A comprehensive analysis of the impact of pseudomonas aeruginosa colonization on prognosis in adult bronchiectasis

Annals of the American Thoracic Society

Volumn 12, Issue 11, 2015, Pages 1602-1611

  Finch, Simon ^a   McDonnell, Melissa J ^b   Abo Leyah, Hani ^a   Aliberti, Stefano ^c   Chalmers, James D ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY HOSPITAL GALWAY   (Ireland)

^c UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

Bacteria; Bronchiectasis; Exacerbations; Mortality; Severity

Indexed keywords

ADULT; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL COLONIZATION; BRONCHIECTASIS; COHORT ANALYSIS; DISEASE EXACERBATION; DISEASE SEVERITY; HOSPITAL ADMISSION; HUMAN; LONGITUDINAL STUDY; LUNG FUNCTION; META ANALYSIS; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PROGNOSIS; PSEUDOMONAS AERUGINOSA; QUALITY OF LIFE; SYSTEMATIC REVIEW; COMPLICATION; DISEASE COURSE; HOSPITALIZATION; ISOLATION AND PURIFICATION; MICROBIOLOGY; ODDS RATIO; PSEUDOMONAS INFECTIONS; SPUTUM;

ANTIINFECTIVE AGENT;

ADULT; ANTI-BACTERIAL AGENTS; BRONCHIECTASIS; DISEASE PROGRESSION; HOSPITALIZATION; HUMANS; OBSERVATIONAL STUDIES AS TOPIC; ODDS RATIO; PROGNOSIS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; QUALITY OF LIFE; SPUTUM;

EID: 84946711281     PISSN: 23296933     EISSN: 23256621     Source Type: Journal    
DOI: 10.1513/AnnalsATS.201506-333OC     Document Type: Article

References (44)

1. Chalmers JD, Aliberti S, Blasi F. Management of bronchiectasis in adults. Eur Respir J 2015;45:1446-1462.
2. Chalmers JD, Smith MP, McHugh BJ, Doherty C, Govan JR, Hill AT. Short-and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2012;186:657-665.
3. Cole PJ. Inflammation: a two-edged sword-the model of bronchiectasis. Eur J Respir Dis Suppl 1986;147:6-15.
4. Chalmers JD, McHugh BJ, Docherty C, Govan JR, Hill AT. Vitamin-D deficiency is associated with chronic bacterial colonisation and disease severity in bronchiectasis. Thorax 2013;68:39-47.
5. Whitters D, Stockley R. Immunity and bacterial colonisation in bronchiectasis. Thorax 2012;67:1006-1013.
6. Rogers GB, Zain NM, Bruce KD, Burr LD, Chen AC, Rivett DW, McGuckin MA, Serisier DJ. A novel microbiota stratification system predicts future exacerbations in bronchiectasis. Ann Am Thorac Soc 2014;11:496-503.
7. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002;34:91-100.
8. Döring G, Hoiby N; Consensus Study Group. Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J Cyst Fibros 2004; 3: 67-91.
9. Langton Hewer SC, Smyth AR. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev 2009;(4):CD004197.
10. Cullen L, McClean S. Bacterial adaptation during chronic respiratory infection. Pathogens 2015;4:66-89.
11. Chalmers JD, Hill AT. Mechanisms of immune dysfunction and bacterial persistence in non-cystic fibrosis bronchiectasis. Mol Immunol 2013;55:27-34.
12. Evans SA, Turner SM, Bosch BJ, Hardy CC, Woodhead MA. Lung function in bronchiectasis: the influence of Pseudomonas aeruginosa. Eur Respir J 1996;9:1601-1604.
13. Davies G, Wells AU, Doffman S, Watanabe S, Wilson R. The effect of Pseudomonas aeruginosa on pulmonary function in patients with bronchiectasis. Eur Respir J 2006;28:974-979.
14. Pasteur MC, Bilton D, Hill AT; British Thoracic Society Bronchiectasis non-CF Guideline Group. British Thoracic Society guideline for non-CF bronchiectasis. Thorax 2010;65(Suppl 1):i1-i58.
15. Haworth CS, Foweraker JE, Wilkinson P, Kenyon RF, Bilton D. Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection. Am J Respir Crit Care Med 2014;189:975-982.
16. Serisier DJ, Bilton D, De Soyza A, Thompson PJ, Kolbe J, Greville HW, Cipolla D, Bruinenberg P, Gonda I; ORBIT-2 investigators. Inhaled, dual release liposomal ciprofloxacin in non-cystic fibrosis bronchiectasis (ORBIT-2): a randomised, double-blind, placebo-controlled trial. Thorax 2013;68:812-817.
17. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB; Meta-analysis Of Observational Studies in Epidemiology (MOOSE) Group. Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA 2000;283:2008-2012.
18. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005;5:13.
19. Hayden JA, Côté P, Bombardier C. Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med 2006;144: 427-437.
20. Chalmers JD, Rother C, Salih W, Ewig S. Healthcare-associated pneumonia does not accurately identify potentially resistant pathogens: a systematic review and meta-analysis. Clin Infect Dis 2014;58:330-339.
21. McDonnell MJ, Jary HR, Perry A, MacFarlane JG, Hester KL, Small T, Molyneux C, Perry JD, Walton KE, De Soyza A. Non cystic fibrosis bronchiectasis: A longitudinal retrospective observational cohort study of Pseudomonas persistence and resistance. Respir Med 2015;109:716-726.
22. Hernández C, Abreu J, Jiménez A, Fernández R, Martí n C. Pulmonary function and quality of life in relation to bronchial colonization in adults with bronchiectasis not caused by cystic fibrosis [in Spanish]. Med Clin (Barc) 2002; 118: 130-134.
23. Kelly MG, Murphy S, Elborn JS. Bronchiectasis in secondary care: a comprehensive profile of a neglected disease. Eur J Intern Med 2003; 14:488-492.
24. Chalmers JD, Goeminne P, Aliberti S, McDonnell MJ, Lonni S, Davidson J, Poppelwell L, Salih W, Pesci A, Dupont LJ, et al. The Bronchiectasis Severity Index: an international derivation and validation study. Am J Respir Crit Care Med 2014;189:576-585.
25. Goeminne PC, Nawrot TS, Ruttens D, Seys S, Dupont LJ. Mortality in non-cystic fibrosis bronchiectasis: a prospective cohort analysis. Respir Med 2014;108:287-296.
26. Loebinger MR, Wells AU, Hansell DM, Chinyanganya N, Devaraj A, Meister M, Wilson R. Mortality in bronchiectasis: a long-term study assessing the factors influencing survival. Eur Respir J 2009;34: 843-849.
27. Martí nez-Garćia MA, de Gracia J, Vendrell Relat M, Girón RM, Máiz Carro L, de la Rosa Carrillo D, Olveira C. Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score. Eur Respir J 2014;43:1357-1367.
28. Wilson CB, Jones PW, O'Leary CJ, Hansell DM, Cole PJ, Wilson R. Effect of sputum bacteriology on the quality of life of patients with bronchiectasis. Eur Respir J 1997;10:1754-1760.
29. King PT, Holdsworth SR, Freezer NJ, Villanueva E, Holmes PW. Microbiologic follow-up study in adult bronchiectasis. Respir Med 2007;101:1633-1638.
30. Tsang KW, Chan K, Ho P, Zheng L, Ooi GC, Ho JC, Lam W. Sputum elastase in steady-state bronchiectasis. Chest 2000;117: 420-426.
31. Hester KLM, Macfarlane JG, Tedd H, Jary H, McAlinden P, Rostron L, Small T, Newton JL, De Soyza A. Fatigue in bronchiectasis. QJM 2012;105:235-240.
32. Miszkiel KA, Wells AU, Rubens MB, Cole PJ, Hansell DM. Effects of airway infection by Pseudomonas aeruginosa: a computed tomographic study. Thorax 1997;52:260-264.
33. Ho PL, Chan KN, Ip MSM, Lam WK, Ho CS, Yuen KY, Tsang KW. The effect of Pseudomonas aeruginosa infection on clinical parameters in steady-state bronchiectasis. Chest 1998;114: 1594-1598.
34. Zheng L, Tipoe G, Lam WK, Ho JC, Shum I, Ooi GC, Leung R, Tsang KW. Endothelin-1 in stable bronchiectasis. Eur Respir J 2000;16: 146-149.
35. Ergan Arsava B, Cöplü L. Does airway colonization cause systemic inflammation in bronchiectasis? Tuberk Toraks 2011;59:340-347.
36. Rogers GB, van der Gast CJ, Cuthbertson L, Thomson SK, Bruce KD, Martin ML, Serisier DJ. Clinical measures of disease in adult non-CF bronchiectasis correlate with airway microbiota composition. Thorax 2013;68:731-737.
37. Wilson CB, Jones PW, O'Leary CJ, Cole PJ, Wilson R. Validation of the St. George's Respiratory Questionnaire in bronchiectasis. Am J Respir Crit Care Med 1997;156:536-541.
38. Martí nez-Garćia MA, Soler-Cataluña JJ, Perpiñá-Tordera M, Román-Sánchez P, Soriano J. Factors associated with lung function decline in adult patients with stable non-cystic fibrosis bronchiectasis. Chest 2007;132:1565-1572.
39. White L, Mirrani G, Grover M, Rollason J, Malin A, Suntharalingam J. Outcomes of Pseudomonas eradication therapy in patients with non-cystic fibrosis bronchiectasis. Respir Med 2012;106:356-360.
40. European Respiratory Society. Bronchiectasis. In: Gibson GJ, Loddenkemper R, Sibille Y, Lundbäck B, editors. European lung white book. Sheffield, UK: European Respiratory Society Publications Office; 2014. pp. 176-183. http://www.erswhitebook. org/chapters/bronchiectasis/
41. Joish VN, Spilsbury-Cantalupo M, Operschall E, Luong B, Boklage S. Economic burden of non-cystic fibrosis bronchiectasis in the first year after diagnosis from a US health plan perspective. Appl Health Econ Health Policy 2013;11:299-304.
42. De Soyza A, Brown JS, Loebinger MR; Bronchiectasis Research & Academic Network. Research priorities in bronchiectasis. Thorax 2013;68:695-696.
43. Chang AB, Bell SC, Torzillo PJ, King PT, Maguire GP, Byrnes CA, Holland AE, O'Mara P, Grimwood K; extended voting group. Chronic suppurative lung disease and bronchiectasis in children and adults in Australia and New Zealand Thoracic Society of Australia and New Zealand guidelines. Med J Aust 2015;202:21-23.
44. Tunney MM, Einarsson GG, Wei L, Drain M, Klem ER, Cardwell C, Ennis M, Boucher RC, Wolfgang MC, Elborn JS. Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation. Am J Respir Crit Care Med 2013;187:1118-1126.